Company Profile
iRadimed simple bio
iRadimed (ticker: IRMD) is an American medical technology company that develops, manufactures, and markets MRI-compatible medical devices. Founded in 2005 and headquartered in Orlando, Florida, the company is a leader in MRI patient care, particularly known for its non-magnetic MRI infusion pumps and patient monitors.
Company Founding
The company was founded by Roger Susi, a biomedical engineer with over 25 years of experience in the medical device industry. Susi previously founded Invivo Research Inc., a pioneer in MRI patient vital sign monitoring.
Founding Mission
iRadimed was founded with the mission of improving patient care by enabling patients to receive necessary infusions and monitoring while undergoing MRI examinations, thus eliminating the need for treatment interruptions or the use of less effective non-MRI-compatible devices.
Initial Public Offering
iRadimed went public on NASDAQ in 2014 under the ticker symbol IRMD.
iRadimed Products
Product Line
iRadimed focuses on developing products that operate safely in the high magnetic field environment of an MRI operating room. Its product line includes:
- MRidium MRI-Compatible Infusion Pump System: Designed to ensure the safe delivery of fluids and medications during MRI scans.
- MRI-Compatible Patient Monitors: Used to monitor patients’ vital signs during imaging examinations.
Awards
- In 2024, iRadimed was named one of Forbes’ most successful small-cap companies in the United States.
- In 2025, the company announced FDA 510(k) approval for a new version of its MRidium Infusion Pump System.
Magnetic Resonance Imaging (MRI)
Advantages of MRI
Many people are curious why MRI still exists and has a considerable market, given the powerful and increasingly widespread use of computed tomography (CT) which has almost replaced the function of MRI. The reason is that, compared to CT, MRI does not involve radiation. This is because Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic technique that uses strong magnetic fields and radio waves to generate high-resolution images of internal human tissues. Its biggest advantage is that it does not use radiation.
MRI Principle
MRI uses a strong magnetic field to rearrange the hydrogen nuclei in human tissues, then uses radio waves to excite them, generating resonance signals, which are then reconstructed into images by a computer.
- Applicable Examinations: Brain, nervous system, spine, joints, soft tissues, abdominal organs, etc.
- Characteristics: No radiation, high contrast for soft tissues, non-invasive.
Computed Tomography (CT) Principle
CT uses an X-ray tube surrounding the body to capture images, which are then processed by a computer to form the final image. Additionally, for some clinical needs, such as evaluating blood vessels in solid lesions or to enhance tissue contrast for more accurate diagnosis, contrast agents may be injected. Common applications include: head, neck, chest, abdomen, and pelvis.
Competitors
- Philips (ticker: PHG)’s Invivo Research: Considered a major competitor, but reports indicate that the company has gradually withdrawn from the market, allowing iRadimed to expand its market share.
- Schiller AG: Known for its MAGLIFE RT-1, a biocompatible MRI monitor, it is a direct competitor to iRadimed’s monitoring solutions.
- GE Healthcare (ticker: GEHC): A major competitor in the medical device field, particularly in biocompatible MRI patient care solutions.
- B. Braun Melsungen AG: Competes in the broader infusion pump market.
- Fresenius Kabi: Another competitor in the infusion pump market.
- MIPM Mammendorfer Institut für Physik und Medizin: Known for producing biocompatible MRI equipment and “Faraday boxes,” which are sometimes used as alternatives to dedicated pumps.
- Kellymed: A Chinese manufacturer that produces low-cost, MRI-compatible infusion pumps, competing in the international market with a price advantage.
Financial Reports
Q4 2025 Financial Report
The following is a summary of the company’s Q4 2025 (ending December 31, 2025) financial report, released on February 10, 2026:
- Revenue: $22.7 million, up 17% year-over-year
- GAAP EPS: $0.50, up 25% year-over-year
- Non-GAAP EPS: $0.54, up 23% year-over-year
- Net Income: $6.4 million, up 25% year-over-year
Full Year 2025 Financial Report
Full year 2025 results are as follows:
- Revenue: $83.8 million (up 14% year-over-year)
- GAAP EPS: $1.75 (up 17% year-over-year)
- Net Income: $22.5 million (up 17% year-over-year)
Capital Market Performance
Market Valuation
As of the end of February 2026, iRadimed’s market capitalization was $1.32 billion. The price-to-earnings ratio (P/E ratio) is 59, with a forward P/E ratio of 45.
Stock Performance
iRadimed’s stock rose 75% by 2025. Since its IPO, it has surged 1,076.82%, achieving tremendous success.
Pros and Cons to invest in iRadimed
Positive side
iRadimed has a small market capitalization, suggesting significant growth potential that could enrich investors. Furthermore, despite its small size, iRadimed is already profitable, a rare occurrence that means it’s unlikely to go bankrupt unless acquired or loses market share.
Investment Risks
The main risk for investors buying iRadimed stock is its overvaluation; currently, its P/E ratio is as high as 56.5, while the industry average is only 30.4.
Another major risk is potential price volatility (daily fluctuation of approximately 2.6%), concentration risk from institutional selling, and pressure to maintain high growth to support its stock price.
Related articles
- “How does HCA Healthcare make money?“
- “Akeso’s lung cancer drug beat world best-selling drug, a biotech DeepSeek watershed“
- “TransMedics, an expert in organ transplant care systems“
- “Intuitive Surgical, a company that essentially monopolizes surgical robots“
- “World’s first gene editing therapy Casgevy finally approved“
- “How does CRISPR, the gene editing inventor, make money?“
- “Abiomed acquired by Johnson & Johnson“
- “How the best AAA credit rating Johnson & Johnson makes money?“
- “How does dominated Intuitive Surgical make money?”
- “Abbott, the world’s most important medical device and nutritional food supplier, how does it make money?“
- “How did three listed companies make money after GE spinoff? What are the prospects?“
Disclaimer
- The content of this site is the author’s personal opinions and is for reference only. I am not responsible for the correctness, opinions, and immediacy of the content and information of the article. Readers must make their own judgments.
- I shall not be liable for any damages or other legal liabilities for the direct or indirect losses caused by the readers’ direct or indirect reliance on and reference to the information on this site, or all the responsibilities arising therefrom, as a result of any investment behavior.
